NCT01895829 is a EARLY_PHASE1 clinical trial of Magnetic Resonance Imaging (MRI) in Head and Neck Cancer, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT01895829?

NCT01895829 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT01895829?

Interventions in NCT01895829: Magnetic Resonance Imaging (MRI), Ferumoxytol.

What condition does NCT01895829 study?

NCT01895829 studies Head and Neck Cancer.

Is NCT01895829 still recruiting?

NCT01895829 is currently terminated. Last updated 21 September 2021.

Last reviewed 2021-09-21 · How we verify

NCT01895829

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI

Terminated EARLY_PHASE1 Last updated 21 September 2021

What this trial tests

EARLY_PHASE1 trial testing Magnetic Resonance Imaging (MRI) in Head and Neck Cancer in 7 participants. Terminated before completion.

Timeline

12 September 2013

Primary endpoint
7 September 2021

7 September 2021

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	EARLY_PHASE1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	7
Start date	12 September 2013
Primary completion	7 September 2021
Estimated completion	7 September 2021
Sites	1 location across United States

Drugs / interventions tested

Magnetic Resonance Imaging (MRI)
Ferumoxytol (FERUMOXYTOL) — full drug profile →

Conditions studied

Head and Neck Cancer — all drugs for Head and Neck Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to learn if ferumoxytol, when given at the time of a magnetic resonance imaging (MRI), can help researchers learn more about the spread of certain kinds of cancers. Ferumoxytol is designed to deliver iron to treat iron-deficiency anemia (low red blood cell counts) in patients with chronic kidney disease. In this study, it will be used as an MRI contrast. Contrasts are used by doctors in order to see MRI images more clearly.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

A Review of Clinical Translation of Inorganic Nanoparticles.
Anselmo AC, Mitragotri S. · · 2015 · cited 263× · PMID 25956384 · DOI 10.1208/s12248-015-9780-2
Nanotechnology in cancer diagnosis: progress, challenges and opportunities.
Zhang Y, Li M, Gao X, Chen Y, et al · · 2019 · cited 227× · PMID 31847897 · DOI 10.1186/s13045-019-0833-3
Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems.
Silva CO, Pinho JO, Lopes JM, Almeida AJ, et al · · 2019 · cited 101× · PMID 30625999 · DOI 10.3390/pharmaceutics11010022
Engineering Iron Oxide Nanoparticles for Clinical Settings.
Cortajarena AL, Ortega D, Ocampo SM, Gonzalez-García A, et al · · 2014 · cited 78× · PMID 30023013 · DOI 10.5772/58841
Clinical Trials of Thermosensitive Nanomaterials: An Overview.
Nardecchia S, Sánchez-Moreno P, Sánchez-Moreno P, Vicente J, et al · · 2019 · cited 60× · PMID 30717386 · DOI 10.3390/nano9020191
A detailed insight of the tumor targeting using nanocarrier drug delivery system.
Batool S, Sohail S, Ud Din F, Alamri AH, et al · · 2023 · cited 56× · PMID 36866455 · DOI 10.1080/10717544.2023.2183815
Nanopharmaceuticals (part 2): products in the pipeline.
Weissig V, Guzman-Villanueva D. · · 2015 · cited 53× · PMID 25709446 · DOI 10.2147/ijn.s65526
Understanding Nanoparticle Toxicity to Direct a Safe-by-Design Approach in Cancer Nanomedicine.
Damasco JA, Ravi S, Perez JD, Hagaman DE, et al · · 2020 · cited 46× · PMID 33147800 · DOI 10.3390/nano10112186

Verify or expand the search:

Other trials of Magnetic Resonance Imaging (MRI)

Trials testing the same drug.

NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting
NCT07346170 — Short Interval Postoperative Stereotactic Body Radiation Therapy (SBRT) After Surgical Intervention for Spine Metastases · NA · not yet recruiting
NCT07110246 — Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas · Phase 2 · recruiting
NCT07185958 — Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy · not yet recruiting
NCT06492057 — Electromyostimulation (EMS) of Astronauts in Spaceflight (Easymotion-2) · NA · enrolling by invitation

Other recruiting trials for Head and Neck Cancer

Currently open trials in the same condition.

NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01895829 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 21 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01895829.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing